As of June 30, 2026, Yarrow Bioscience, Inc. carries a market capitalization of 91.20M, placing it among publicly traded companies globally. Its enterprise value stands at 68.27M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 91.20M |
| Enterprise Value | 68.27M |
Yarrow Bioscience, Inc.'s next confirmed earnings release is scheduled for March 4, 2027.
| Earnings Date | 3/4/2027 |
As of June 30, 2026, Yarrow Bioscience, Inc. has 2.80M shares outstanding.
| Shares Outstanding | 2.80M |
These figures are as of June 30, 2026. The price-to-sales ratio is 85.63, and the price-to-book ratio stands at 4.13.
| PS Ratio | 85.63 |
| PB Ratio | 4.13 |
| P/TBV Ratio | 4.13 |
These figures are as of June 30, 2026. The EV/Sales ratio of 411.28 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 68.27M versus a market cap of 91.20M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 411.28 |
As of June 30, 2026, Yarrow Bioscience, Inc. maintains a current ratio of 15.26, meaning it holds 15.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 15.26 |
| Quick Ratio | 14.87 |
These figures cover the twelve months ended June 30, 2026. The company generates approximately 16,600.00 in revenue per employee across its workforce of 10.00, a quick read on workforce productivity versus industry peers.
| Revenue Per Employee | 16,600.00 |
| Employee Count | 10.00 |
These figures are as of the close on November 16, 2026.
| 50-Day Moving Average | 21.55 |
Over the twelve months ended June 30, 2026, Yarrow Bioscience, Inc. generated 166,000.00 in revenue and converted that into -82.50M in net income, yielding earnings per share of -188.57. EBITDA reached -84.50M, while operating income came in at -14.50M.
| Revenue | 166,000.00 |
| Operating Income | -14.50M |
| Pretax Income | -82.38M |
| Net Income | -82.50M |
| EBITDA | -84.50M |
| EBIT | -84.50M |
| Earnings Per Share (EPS) | -188.57 |
These figures are as of June 30, 2026. Total book value stands at 22.06M, with working capital of 21.98M providing operational flexibility.
| Cash & Cash Equivalents | 22.93M |
| Net Debt | -22.92M |
| Equity (Book Value) | 22.06M |
| Book Value Per Share | 7.87 |
| Working Capital | 21.98M |
These figures cover the twelve months ended June 30, 2026. The operating margin of -8,734.94 and net profit margin of -49,699.40 provide insight into operational efficiency.
| Operating Margin | -8,734.94 |
| Pretax Margin | -49,629.52 |
| Profit Margin | -49,699.40 |
| EBITDA Margin | -50,903.61 |
Yarrow Bioscience, Inc.'s most recent stock split took place on July 27, 2026 with a 50:1 split ratio.
| Last Split Date | 7/27/2026 |
| Split Ratio | 50:1 |
As of June 30, 2026, Yarrow Bioscience, Inc. has an Altman Z-Score of -10.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -10.75 |